WO2006082820A1 - 性器ヘルペス治療剤 - Google Patents
性器ヘルペス治療剤 Download PDFInfo
- Publication number
- WO2006082820A1 WO2006082820A1 PCT/JP2006/301614 JP2006301614W WO2006082820A1 WO 2006082820 A1 WO2006082820 A1 WO 2006082820A1 JP 2006301614 W JP2006301614 W JP 2006301614W WO 2006082820 A1 WO2006082820 A1 WO 2006082820A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- thiopyran
- tetrahydro
- amino
- lesions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Definitions
- the present invention relates to a novel therapeutic agent for genital herpes.
- Genital herpes are mainly herpes simplex virus type 2 (HSV-2) and partly herpes simplex virus type 1 (HSV-2) -It is estimated that it is a sexually transmitted disease that develops due to the infection of 1), and has many patient powers mainly in Europe and the United States. Since genital herpes develops a pathological condition characterized by severe pain along with lesions such as blisters, sores, and ulceration associated with the growth of HSV around the genital area after HSV infection, the patient's physical condition It has been raised as one of the major diseases of mental distress.
- nucleic acid drugs such as acyclovir (ACV) and its prodrugs valacyclovir (VCV) and fanciclovir (FCV) are used as therapeutic agents.
- ACCV acyclovir
- VCV valacyclovir
- FCV fanciclovir
- the applicant of the present invention directly substituted an aryl or heteroaryl group which is an aromatic ring group as a group A on the N atom of the amide group represented by the following formula having good anti-herpesvirus activity.
- Patent Document 1 and Patent Document 2 there is no disclosure of the effects on genital herpes after onset.
- Ri, R 2 are H, mono-lower alkyl, NRaRb, etc.
- A is an optionally substituted aryl, -an optionally substituted heteroaryl, etc. Is CO or SO
- R 3 represents an aryl optionally having a substituent, a heterocyclic ring optionally having a substituent, and the like. See the official gazette for details. )
- Patent Document 3 Patent Document 3 by the present applicant, etc. published after the priority date of the present application discloses a compound represented by the following formula. However, there is no disclosure of the effect of the compound on genital herpes after onset.
- Z represents 1, 2, 4 oxazodiol 3-yl, 4-oxazolyl, etc.
- A represents an aryl having an optionally substituted group
- X represents CO or SO
- R 3 represents Have a substituent
- Patent Document 1 Pamphlet of International Publication No. 02/38554
- Patent Document 2 International Publication No. 03/95435 Pamphlet
- Patent Document 3 International Publication No. 05/014559 Pamphlet
- the present invention provides a novel N— ⁇ 2-[(4-substituted phenyl) amino] 2 -oxoethyl ⁇ tetrahydro-1H thiopyran 4 carboxamido compound represented by the following general formula (I):
- the present invention relates to a therapeutic agent for post-onset genital herpes.
- A substituted with at least one methyl group, and further having 1 to 2 substituents selected from the group consisting of a methyl group and a halogen atom, a phenyl group, or a 5-indyl group Group. The same applies below. )
- a compound having a Z force of 1, 2, 4 oxaziazol 3-yl group (1) A compound having a Z force of 1, 2, 4 oxaziazol 3-yl group.
- a force I is it substituted with at least one methyl group, and is a A compound which is a phenyl group optionally having 1 to 2 substituents
- the present invention also provides an N— ⁇ 2 -— ((4-substituted-phenol) amino] 2 -oxoethyl ⁇ tetrahydro- ol represented by the above general formula (I) for producing a therapeutic agent for genital herpes after the onset of lesions
- the present invention also relates to a method for treating genital herpes after onset of lesions, comprising administering opiran-4-carboxamide compound to a mammal.
- the compound (I), which is an active ingredient of the present invention has a good anti-herpesvirus action, and exhibits a good therapeutic effect on genital herpes after lesion onset
- the medicament of the present invention is useful for the treatment of genital herpes after the onset of lesions associated with infection.
- “norogen atom” includes F, Cl, Br, and I atoms.
- N— ⁇ 2 -— [(4-substituted phenol) amino] 2 oxoethyl ⁇ tetrahydro 2H thiopyran 4 carboxamido compound represented by the general formula (I) of the present invention includes hydrates and various solvents. Japanese and polymorphic substances are also included.
- the functional group may be replaced with an appropriate protecting group at the raw material or intermediate stage, that is, a group that can be easily transferred to the functional group. May be effective in manufacturing technology. Thereafter, the protective group can be removed as necessary to obtain the desired compound.
- functional groups include amino groups, hydroxyl groups, carboxyl groups and the like, and examples of protective groups thereof include, for example, Protective Groups in Organic Synthesis d / 3 ⁇ 43 ⁇ 4 (by TW tureen and PGM Wuts, JOHN Protecting groups described in WILLY & SONS, INC.), which may be used as appropriate depending on the reaction conditions.
- the methods described in the reference can be applied in a timely manner.
- Compound (I) can be easily produced by subjecting the carboxylic acid compound (III) and the arin derivative (II) to an amidy reaction.
- the amid ⁇ reaction can be carried out by a conventional method.
- the method described in “Chemical Experiment Course” edited by The Chemical Society of Japan, 4th edition (Maruzen) 22 ⁇ pl37-173 can be applied.
- the carboxylic acid compound (III) is converted into a reactive derivative such as an acid halide (acid chloride or the like) or an acid anhydride, and then reacted with the aline derivative (II). Can do.
- a reactive derivative of carboxylic acid it is preferable to add a base (an inorganic base such as potassium carbonate or sodium hydroxide, or an organic base such as triethylamine (TEA), diisopropylethylamine, pyridine).
- a base an inorganic base such as potassium carbonate or sodium hydroxide, or an organic base such as triethylamine (TEA), diisopropylethylamine, pyridine.
- Amido® can be used in the presence of condensing agents such as 1-ethyl-3- (3 dimethylaminopropyl) carbodiimide (WSC), 1,1, monocarbonylbis-1H-imidazole (CDI), etc. It can also be performed by reacting. At that time, an additive such as 1-hydroxybenzotriazole (HOBt) may be added.
- the reaction temperature can be appropriately selected depending on the raw material compound.
- Solvents are inert to the reaction, for example, aromatic hydrocarbon solvents such as benzene and toluene, ether solvents such as tetrahydrofuran (THF) and 1,4 dioxane, and halogenated hydrocarbons such as dichloromethane and chloroform.
- System solvents amide solvents such as N 2, N dimethylformamide (DMF) and N, N dimethylacetamide, and basic solvents such as pyridine.
- the solvent is appropriately selected according to the type of raw material and the like, and used alone or in combination.
- Each of the above raw material compounds can be easily produced by using a known reaction, for example, a reaction described in “Chemical Experiment Course” (Maruzen) edited by The Chemical Society of Japan or pamphlet of International Publication No. 02/38554. it can.
- the typical production method is shown below.
- Hal represents halogen
- R represents a group capable of forming an ester residue such as lower alkyl or aralkyl.
- amidyl can be carried out in the same manner as described in the first production method.
- N alkylation of the compound (VI) is carried out using the halogenated alkyl compound (VII) by a conventional method, for example, the method described in “Experimental Chemistry Course” 4th edition (Maruzen), p. be able to.
- the reaction temperature can be carried out under cooling to heating, and examples of the solvent include a solvent inert to the reaction, such as a solvent exemplified in the amidation of the first production method.
- the reaction is preferably carried out in the presence of a base such as potassium carbonate, sodium hydroxide or sodium hydride.
- Amidation can be carried out in the same manner as in the first production method.
- N-alkylation may be carried out after amidation is carried out first.
- Deprotection for obtaining the carboxylic acid compound (III) can be carried out by appropriately applying a conventional method depending on the type of ester.
- alkyl esters such as ethyl ester are treated with a base such as an aqueous sodium hydroxide solution, and aralkyl esters such as benzyl ester are reduced with palladium on carbon (Pd-C) in a hydrogen atmosphere.
- Pd-C palladium on carbon
- substituent it can be further subjected to a substituent modification reaction well known to those skilled in the art to produce a desired raw material compound.
- the compound (I), which is the active ingredient of the present invention thus produced is isolated or purified as a salt after being free or subjected to a salt formation treatment by a conventional method. Isolation 'Purification is performed by applying ordinary chemical operations such as extraction, concentration, distillation, crystallization, filtration, recrystallization, and various chromatography. [0015]
- the medicament of the present invention containing one or more compounds (I) as an active ingredient is usually used in the art, and is usually used using a pharmaceutical carrier, excipient, or the like. It can be prepared by the method used.
- Administration is oral by tablet, pill, capsule, granule, powder, liquid, etc., or injection such as intravenous injection, intramuscular injection, ointment, plaster, cream, jelly, poultice, spray It may be in a misaligned form for parenteral administration using an external preparation such as an agent, lotion, eye drop, eye ointment, suppository or inhalant.
- injection such as intravenous injection, intramuscular injection, ointment, plaster, cream, jelly, poultice, spray It may be in a misaligned form for parenteral administration using an external preparation such as an agent, lotion, eye drop, eye ointment, suppository or inhalant.
- solid compositions for oral administration tablets, powders, granules and the like are used.
- one or more active substances at least one inert excipient such as lactose, mannitol, dextrose, hydroxypropyl cellulose, microcrystalline cellulose, starch, polybule Mixed with pyrrolidone, magnesium metasilicate aluminate, etc.
- the composition may contain an inert additive, for example, a lubricant such as magnesium stearate, a disintegrant such as sodium carboxymethyl starch, and a solubilizing agent according to a conventional method. Tablets or pills may be coated with sugar coating or gastric or enteric coating agent if necessary.
- Liquid compositions for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, elixirs, etc., and generally used inert solvents such as purified water, ethanol Etc. can be used.
- this composition may contain solubilizers, moisturizers, suspending agents and other adjuvants, sweeteners, flavoring agents, fragrances, and preservatives.
- Injections for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions.
- aqueous solvent include distilled water for injection and physiological saline.
- Non-aqueous solvents include, for example, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, alcohols such as ethanol, polysorbate 80 (pharmaceutical name), and the like.
- Such compositions may further contain isotonic agents, preservatives, wetting agents, emulsifiers, dispersants, stabilizers, and solubilizing agents. These are sterilized by, for example, filtration through a bacteria-retaining filter, blending with a bactericide or irradiation.
- External preparations include ointments, plasters, creams, jellies, poultices, sprays, lotions, eye drops, eye ointments and the like. Contains commonly used ointment bases, lotion bases, aqueous or non-aqueous solutions, suspensions, emulsions, and the like.
- ointment or lotion bases include polyethylene glycol, propylene glycol, white petrolatum, white beeswax, polyoxyethylene hydrogenated castor oil, glyceryl monostearate, stearyl alcohol, cetyl alcohol, lauromacrogol, sonorebitan sesquioleate, carbo Xybule polymer and the like can be mentioned.
- the daily dose of Compound (I), which is the active ingredient of the present invention is usually about 0.001 force or 50 mg / kg per body weight in oral administration, preferably 0.01 to 30 mg. / kg, more preferably ⁇ , 0.05-: LOmgZkg force
- the daily dose is about 0.001 force and 10 mgZkg per body weight, preferably 0.001 to 1. OmgZkg respectively. It is appropriate to administer this once or several times a day.
- the dosage is appropriately determined according to individual cases in consideration of symptoms, age, sex, and the like.
- an external preparation containing Compound (I) in an amount of 0.0001 to 20%, preferably 0.01 to 10% is preferable. This is given topically once or several times daily depending on the symptoms.
- Example 1 Guinea pig HSV-2 genital herpes model post-onset therapeutic effect
- HSV-2 vaginal infectious organ herpes model in guinea pigs. Insert a cotton swab soaked in HSV-2 virus solution (HSV-2 G strain 1.25 x 10 5 PFU / mL) into the vagina of a Hartley female guinea pig (4 weeks old) under jetyl ether anesthesia. Infected. Vaginal lesions and systemic symptoms due to HSV-2 infection were scored in the following 6 levels and evaluated daily from the day of infection (day 0) to 9 days after infection.
- Score 3 50-100% blister formation per vaginal visible area
- Score 4 10-50% ulceration per vaginal visible area
- vaginal lesions due to HSV-2 infection that is, 4 days after infection
- guinea pigs with a vaginal lesion score of 1 or 2 and the onset of disease were selected, so that the average score was equal.
- administration of the test compound was started.
- the test compound was orally administered as a methylcellulose suspension twice a day for 5 days from 4 days to 8 days after infection.
- a comparative study in which administration was started before the onset of vaginal lesions (3 hours after HSV-2 infection) and administered in the same manner until 4 days after infection was conducted simultaneously. went.
- Each test consists of 10 guinea pigs per group with VCV as the control compound.
- the following table shows the results of determining the dose (ED value; mg / kg, twice a day) of the test compound that suppresses the placebo-treated score by 50% with respect to the average vaginal lesion score 9 days after HSV-2 infection.
- VCV a comparative compound
- VCV administration is started after the onset of lupus lesions, 1 in the test of deviation, the ED value is calculated to be 300 (mg / kg, twice a day) or more, and VCV The effect of improving lesions
- the ED values of the compounds of Production Examples 2 and 27 of the present invention are 3.1 and 2.5 (mg / kg, twice a day)
- the pharmaceutical agent of the present invention has a good improvement effect even after administration after the onset of genital herpes lesions.
- the compound of the present invention has a good therapeutic effect on genital herpes after onset of lesion unlike a conventional anti-herpes virus agent. .
- the compound of the present invention is not a nucleic acid system and exhibits good activity, it was expected that the compound of the present invention could be a safer therapeutic agent for genital herpes after onset of lesions.
- Reference Example 1 After adding 4% (4-tropheol) 1,3 oxazole ethanol and tetrahydride mouth furan with 5% palladium on carbon powder and stirring at room temperature under hydrogen atmosphere for 12 hours. The reaction solution was filtered through Celite, and the filtrate was distilled off under reduced pressure. The resulting crude product was purified by silica gel column chromatography to obtain [4- (1,3-oxazole-4-yl) phenol] amine (pale yellow solid). Electron Impact- MS ( ⁇ : 160.
- Reference Example 2 Potassium carbonate and ethyl bromoacetate were added to a DMF solution of 4-methyl-line and stirred with heating. After adding water and ethyl acetate to the reaction mixture, the organic layer was separated, washed and dried, and then the solvent was distilled off under reduced pressure to obtain a crude product. This was dissolved in methylene chloride, and pyridine, tetrahydro-2H thiopyran-4 carbohydride 1, 1-dioxide was added and stirred. The reaction solution was concentrated, 1M hydrochloric acid and chloroform were added, the organic layer was separated, washed and dried, and the solvent was evaporated under reduced pressure.
- Reference Examples 3 to 15 The compounds of Reference Examples 3 to 15 described in Table 2 below were obtained in the same manner as in Reference Example 2.
- the obtained crude carboxylic acid product was dissolved in black mouth form (15 mL), and then WSC'HCl (422 mg), [4- (1,3-oxazole 4-yl) phenol] amine (320 mg) was added. The mixture was sequentially stirred at room temperature for 4 hours. A saturated aqueous sodium bicarbonate solution and black mouth form were added to the reaction solution, and then the organic layer was separated. Further, the organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, filtered, and then the solvent was distilled off under reduced pressure.
- Production Examples 2 to 40 The compounds of Production Examples 2 to 40 shown in Table 3 to LO below were obtained in the same manner as in Production Example 1.
- Compound (I) which is an active ingredient of the present invention has a good anti-herpesvirus activity
- the medicament of the present invention is useful for the treatment of genital herpes after the onset of lesions associated with infection.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/815,390 US20090030049A1 (en) | 2005-02-02 | 2006-02-01 | Medicament for genital herpes |
CA002596850A CA2596850A1 (en) | 2005-02-02 | 2006-02-01 | Medicament for genital herpes |
EP06712757A EP1844775B1 (en) | 2005-02-02 | 2006-02-01 | Therapeutic agent for the treatment of herpes progenitalis after development of lesions |
DE602006016069T DE602006016069D1 (de) | 2005-02-02 | 2006-02-01 | Therapeutischer wirkstoff zur behandlung von herpes progenitalis nach der entwicklung von läsionen |
JP2007501577A JPWO2006082820A1 (ja) | 2005-02-02 | 2006-02-01 | 性器ヘルペス治療剤 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005-027108 | 2005-02-02 | ||
JP2005027108 | 2005-02-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006082820A1 true WO2006082820A1 (ja) | 2006-08-10 |
Family
ID=36777204
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/301614 WO2006082820A1 (ja) | 2005-02-02 | 2006-02-01 | 性器ヘルペス治療剤 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20090030049A1 (ja) |
EP (1) | EP1844775B1 (ja) |
JP (1) | JPWO2006082820A1 (ja) |
CA (1) | CA2596850A1 (ja) |
DE (1) | DE602006016069D1 (ja) |
ES (1) | ES2347681T3 (ja) |
WO (1) | WO2006082820A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010047295A1 (ja) | 2008-10-20 | 2010-04-29 | アステラス製薬株式会社 | 帯状疱疹関連痛の予防又は治療薬 |
JP5381978B2 (ja) * | 2008-04-02 | 2014-01-08 | アステラス製薬株式会社 | アミド誘導体含有医薬組成物 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020038812A1 (en) | 2018-08-20 | 2020-02-27 | Rijksuniversiteit Groningen | New process for the preparation of amenamevir |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002038554A1 (fr) * | 2000-11-10 | 2002-05-16 | Yamanouchi Pharmaceutical Co., Ltd. | Derives amides |
WO2003095435A1 (fr) * | 2002-05-09 | 2003-11-20 | Yamanouchi Pharmaceutical Co., Ltd. | Derives d'amides |
WO2005014559A1 (ja) * | 2003-08-08 | 2005-02-17 | Astellas Pharma Inc. | アミド誘導体 |
-
2006
- 2006-02-01 DE DE602006016069T patent/DE602006016069D1/de active Active
- 2006-02-01 EP EP06712757A patent/EP1844775B1/en not_active Not-in-force
- 2006-02-01 ES ES06712757T patent/ES2347681T3/es active Active
- 2006-02-01 JP JP2007501577A patent/JPWO2006082820A1/ja not_active Withdrawn
- 2006-02-01 CA CA002596850A patent/CA2596850A1/en not_active Abandoned
- 2006-02-01 WO PCT/JP2006/301614 patent/WO2006082820A1/ja active Application Filing
- 2006-02-01 US US11/815,390 patent/US20090030049A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002038554A1 (fr) * | 2000-11-10 | 2002-05-16 | Yamanouchi Pharmaceutical Co., Ltd. | Derives amides |
WO2003095435A1 (fr) * | 2002-05-09 | 2003-11-20 | Yamanouchi Pharmaceutical Co., Ltd. | Derives d'amides |
WO2005014559A1 (ja) * | 2003-08-08 | 2005-02-17 | Astellas Pharma Inc. | アミド誘導体 |
Non-Patent Citations (1)
Title |
---|
See also references of EP1844775A4 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5381978B2 (ja) * | 2008-04-02 | 2014-01-08 | アステラス製薬株式会社 | アミド誘導体含有医薬組成物 |
WO2010047295A1 (ja) | 2008-10-20 | 2010-04-29 | アステラス製薬株式会社 | 帯状疱疹関連痛の予防又は治療薬 |
Also Published As
Publication number | Publication date |
---|---|
EP1844775A1 (en) | 2007-10-17 |
EP1844775B1 (en) | 2010-08-11 |
US20090030049A1 (en) | 2009-01-29 |
EP1844775A4 (en) | 2008-09-10 |
DE602006016069D1 (de) | 2010-09-23 |
CA2596850A1 (en) | 2006-08-10 |
ES2347681T3 (es) | 2010-11-03 |
JPWO2006082820A1 (ja) | 2008-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100866820B1 (ko) | 지질 풍부 플라크 퇴축제 | |
TWI434842B (zh) | Azole compounds | |
CN101268060A (zh) | 噻唑啉酮和噁唑啉酮类化合物及其作为ptp1b抑制剂的应用 | |
KR20000070983A (ko) | 3-피페리딜-4-옥소퀴나졸린 유도체 및 그를 함유하는 의약 조성물 | |
TWI729443B (zh) | 做為組蛋白去乙醯酶6抑制劑之1,3,4-㗁二唑衍生物及包含彼之醫藥組合物 | |
WO2020107500A1 (zh) | 2-(1-酰氧正戊基)苯甲酸与碱性氨基酸或氨基胍形成的盐、其制备方法及用途 | |
JPH0541626B2 (ja) | ||
JPWO2005014559A1 (ja) | アミド誘導体 | |
WO2014142219A1 (ja) | グアニジノ安息香酸エステル化合物 | |
JPH0662562B2 (ja) | ピロール酢酸アミド | |
WO2006082821A1 (ja) | ヘルペスウイルスが関与する疾患の予防若しくは治療剤 | |
JP7012289B2 (ja) | ベンゾイルグリシン誘導体およびその作製および使用の方法 | |
JPH08512038A (ja) | 胃腸障害の治療に関するフェネタノールアミン誘導体の用途 | |
WO2006082820A1 (ja) | 性器ヘルペス治療剤 | |
CN112759545B (zh) | 3-(二甲氨基甲基)哌啶-4-醇类衍生物及其制备方法和药物用途 | |
JP5011739B2 (ja) | テトラヒドロ−2h−チオピラン−4−カルボキサミド誘導体を含有する医薬組成物 | |
JPH033671B2 (ja) | ||
JPH11509520A (ja) | 鎮痛特性を有する新規のn−アセチル化4−ヒドロキシフェニルアミン誘導体及びそれを含む薬理組成物 | |
WO2003095435A1 (fr) | Derives d'amides | |
WO2006082822A1 (ja) | アシクロビル耐性ヘルペスウイルスによる疾患の予防・治療剤 | |
JP2790335B2 (ja) | 共役γ―オキシブテノライド化合物およびこれを有効成分とする抗潰瘍剤 | |
CN115304590B (zh) | 2h-苯并三氮唑衍生物及其制备方法及含有它们的药物组合物 | |
JP3623228B1 (ja) | テトラヒドロ−2h−チオピラン−4−カルボキサミド誘導体 | |
CN115872930A (zh) | N-取代3,4-二氢异喹啉-1(2h)-酮衍生物、其组合物及其在药物中的应用 | |
WO2001000588A1 (fr) | Composes de benzimidazole et medicaments les contenant |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007501577 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006712757 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11815390 Country of ref document: US Ref document number: 2596850 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 2006712757 Country of ref document: EP |